BR112021024438A2 - Métodos e composições para tratar câncer com carreadores de fármaco de ligação de colágeno - Google Patents
Métodos e composições para tratar câncer com carreadores de fármaco de ligação de colágenoInfo
- Publication number
- BR112021024438A2 BR112021024438A2 BR112021024438A BR112021024438A BR112021024438A2 BR 112021024438 A2 BR112021024438 A2 BR 112021024438A2 BR 112021024438 A BR112021024438 A BR 112021024438A BR 112021024438 A BR112021024438 A BR 112021024438A BR 112021024438 A2 BR112021024438 A2 BR 112021024438A2
- Authority
- BR
- Brazil
- Prior art keywords
- collagen
- drug carriers
- compositions
- methods
- treating cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856468P | 2019-06-03 | 2019-06-03 | |
| PCT/US2020/070113 WO2020247974A1 (en) | 2019-06-03 | 2020-06-03 | Methods and compositions for treating cancer with collagen binding drug carriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024438A2 true BR112021024438A2 (pt) | 2022-02-15 |
Family
ID=73652058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024438A BR112021024438A2 (pt) | 2019-06-03 | 2020-06-03 | Métodos e composições para tratar câncer com carreadores de fármaco de ligação de colágeno |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220298225A1 (https=) |
| EP (1) | EP3976111A4 (https=) |
| JP (2) | JP7680375B2 (https=) |
| CN (1) | CN114173822B (https=) |
| AU (1) | AU2020289485A1 (https=) |
| BR (1) | BR112021024438A2 (https=) |
| CA (1) | CA3144535A1 (https=) |
| MX (1) | MX2021014932A (https=) |
| WO (1) | WO2020247974A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2024177006A1 (https=) * | 2023-02-20 | 2024-08-29 | ||
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101808751B1 (ko) * | 2009-11-13 | 2017-12-13 | 그리폴스 테라퓨틱스 인코포레이티드 | 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| JP6508785B2 (ja) * | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| EP3094650A2 (en) * | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| WO2016033331A1 (en) * | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| WO2016054107A1 (en) * | 2014-09-29 | 2016-04-07 | Counterpoint Biomedica Llc | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers |
| WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| AU2019366956B2 (en) * | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
-
2020
- 2020-06-03 BR BR112021024438A patent/BR112021024438A2/pt unknown
- 2020-06-03 CN CN202080055104.6A patent/CN114173822B/zh active Active
- 2020-06-03 CA CA3144535A patent/CA3144535A1/en active Pending
- 2020-06-03 WO PCT/US2020/070113 patent/WO2020247974A1/en not_active Ceased
- 2020-06-03 JP JP2021571671A patent/JP7680375B2/ja active Active
- 2020-06-03 EP EP20818032.3A patent/EP3976111A4/en active Pending
- 2020-06-03 AU AU2020289485A patent/AU2020289485A1/en active Pending
- 2020-06-03 US US17/596,118 patent/US20220298225A1/en active Pending
- 2020-06-03 MX MX2021014932A patent/MX2021014932A/es unknown
-
2025
- 2025-05-08 JP JP2025077691A patent/JP2025121986A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020247974A1 (en) | 2020-12-10 |
| JP2025121986A (ja) | 2025-08-20 |
| AU2020289485A1 (en) | 2022-02-03 |
| CN114173822A (zh) | 2022-03-11 |
| JP7680375B2 (ja) | 2025-05-20 |
| US20220298225A1 (en) | 2022-09-22 |
| CA3144535A1 (en) | 2020-12-10 |
| CN114173822B (zh) | 2025-01-10 |
| EP3976111A1 (en) | 2022-04-06 |
| EP3976111A4 (en) | 2023-07-05 |
| JP2022535816A (ja) | 2022-08-10 |
| MX2021014932A (es) | 2022-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019022972A2 (pt) | Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas | |
| PE20181365A1 (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos | |
| MX2025008340A (es) | Anticuerpos humanizados contra c-kit | |
| ZA202405748B (en) | Universal abt compounds and uses thereof | |
| WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| EP4378962A3 (en) | Anti-cancer fusion polypeptide | |
| EP4233909A3 (en) | Anti-cmet antibody drug conjugates and methods for their use | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| BR112012029280A2 (pt) | variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| MX360671B (es) | Composición farmacéutica para el tratamiento y/o prevención del cáncer. | |
| BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
| WO2018081726A3 (en) | Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis | |
| CL2021001564A1 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores (divisional de la solicitud no. 201702407) | |
| BR112022008552A2 (pt) | Moléculas de ligação multiespecíficas de scfv de terminal-n | |
| CY1126032T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap | |
| MX2020002802A (es) | Anticuerpos de cadena pesada que se unen a ectoenzimas. | |
| BR112021024438A2 (pt) | Métodos e composições para tratar câncer com carreadores de fármaco de ligação de colágeno | |
| BR112017001093A2 (pt) | formulação aquosa compreendendo paracetamol e ibuprofeno | |
| WO2017062615A3 (en) | Combination therapy for the treatment of cancer | |
| BR112014016723A2 (pt) | método para o tratamento de câncer de mama | |
| BR112021024997A2 (pt) | Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso |